Verrica Pharmaceuticals Trading Halted: News Pending

Verrica Pharmaceuticals' trading has been halted pending news.

Verrica Pharmaceuticals (VRCA, Financial) has experienced a trading halt, with an announcement expected soon. Investors are eagerly awaiting updates that could provide clarity on the situation. The trading pause has sparked curiosity among stakeholders, as they anticipate potential news that might impact the stock's trajectory. The company's next steps are keenly watched by market participants.

Based on the one-year price targets offered by 2 analysts, the average target price for Verrica Pharmaceuticals Inc (VRCA, Financial) is $4.00, with a high estimate of $5.00 and a low estimate of $3.00. The average target implies a downside of 42.86% from the current price of $7.00 [1].

The consensus recommendation from 5 brokerage firms indicates that Verrica Pharmaceuticals Inc's (VRCA, Financial) average brokerage recommendation is currently 2.4, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies a Strong Buy, and 5 denotes a Sell [1].

GuruFocus estimates that the estimated GF Value for Verrica Pharmaceuticals Inc (VRCA, Financial) in one year is $2.41, suggesting a downside of 65.57% from the current price of $7.00. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at, calculated based on historical multiples and future estimates of the business' performance [1].

Verrica Pharmaceuticals Inc (VRCA, Financial) reported $3.4 million in revenue for the first quarter of 2025, primarily from YCANTH. The company's gross product margin was approximately 88%, and the cost of product revenue was $0.4 million, including $47,000 of obsolete inventory cost. Research and development expenses decreased to $2.3 million, and selling, general, and administrative expenses decreased to $8.8 million. The company reported a GAAP net loss of $9.7 million and a non-GAAP net loss of $7.8 million for the first quarter of 2025. Cash and cash equivalents stood at $29.6 million as of March 31, 2025 [2].

Verrica Pharmaceuticals Inc (VRCA, Financial) has announced a 1-for-10 reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on Thursday. The reverse stock split will become effective when the market opens on Friday. The new CUSIP number for the common stock will be 92511W207. As of July 11, 2025, the company reported approximately 92.5 million shares of common stock outstanding. Immediately after the reverse split, this number will be reduced to approximately 9.25 million shares, subject to adjustment for fractional shares [3].

References:
[1] https://www.gurufocus.com/news/3004047/vrca-trading-halted-anticipation-builds-for-pending-announcement-vrca-stock-news
[2] https://www.nasdaqtrader.com/Trader.aspx?id=currentheadlines
[3] https://za.investing.com/news/sec-filings/verrica-pharmaceuticals-to-implement-1for10-reverse-stock-split-93CH-3800709